The patents may be over, but the rights for Plavix and Avapro are still worthy of a deal. The latest deal is that BMS is letting Sanofi have the rights to Plavix back, except for the US and Puerto Rico. The deal gives BMS a royalty cut on branded and unbranded Plavix sales worldwide (except for the US) as well as on branded and unbranded Avapro sales worldwide.
Novartis presented data from its global EDGE study that the company said shows that "a significantly higher proportion" of type 2 diabetes patients responded to treatment with Galvus (vildagliptin), along with existing oral anti-diabetes therapy, or Eucreas (vildagliptin plus metformin), compared to combos of other oral anti-diabetes treatments. The data showed a 1.9% reduction in HbA1c when vildagliptin was added to existing oral anti-diabetes therapies.